Real-world data comparison of time to next treatment for patients with HER2 low metastatic treated with either chemotherapy or fam-trastuzumab deruxtecan-nxki following chemotherapy in the metastatic setting

被引：0
|
作者：
Gorantla, Vikram C.
Rui, Anna
Rosenfeld, Stephan B.
Kudrik, Fred J.
Vasudevan, Anupama
Sura, Teena
Gart, Mike
Kanovsky, Doug
Brenneman, Dawn
Varughese, Prateesh
Scott, Jeffrey A.
Choksi, Rushir J.
Geller, Robert B.
Blanc, Simon
机构：
[1] Univ Pittsburgh Med Ctr, Pittsburgh, PA USA
[2] Integra Connect PrecisionQ, W Palm Beach, FL USA
[3] Highlands Oncol Grp, Fayetteville, AR USA
[4] South Carolina Oncol Associates, W Columbia, SC USA
[5] Integra Connect, W Palm Beach, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13169
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Survival Outcomes of Metastatic or Recurrent Cervical Cancer Patients Treated with Palliative Intent Chemotherapy: Real-World Data
    Rath, Sushmita
    Elamarthi, Prahalad
    Ghosh, Jaya
    Gulia, Seema
    Bajpai, Jyoti
    Mittal, Prachi
    Gurram, Lavanya
    Kulkarni, Rohini
    Dash, Biswajit
    Rekhi, Bharat
    Menon, Santosh
    Deodhar, Kedar
    Baheti, Akshay
    Sable, Nilesh
    Popat, Palak
    Maheshwari, Amita
    Chopra, Supriya
    Gupta, Sudeep
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 22 (04)
  • [22] Survival of patients with metastatic HER2 positive gastroesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on frontline chemotherapy plus trastuzumab.
    Moser, Justin
    Solomon, Benjamin
    Nevala-Plagemann, Christopher Duane
    Gilcrease, Glynn Weldon
    Whisenant, Jonathan R.
    Garrido-Laguna, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [23] HER2 expression and HER2:HER2 dimerization identifies subpopulations of metastatic breast cancer patients with different probabilities of long-term survival following trastuzumab treatment and with different requirements for concomitant chemotherapy
    Bates, M. P.
    Desmedt, C.
    Sperinde, J.
    Huang, W.
    Larsimont, D.
    Durbecq, V.
    Winslow, J.
    Chappey, C.
    Piccart, M.
    Sotiriou, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy
    Paulissen, Jeroen Hendrikus Jacobus
    van Schoonhoven, Alexander Victor
    Olin, Emma
    Postma, Arjan Jacobus
    Mbanya, Zacharie
    Dunton, Kyle John
    Postma, Maarten Jacobus
    van Hulst, Marinus
    Freriks, Roel Donald
    ADVANCES IN THERAPY, 2025, 42 (01) : 322 - 333
  • [25] Real-World data of triplet combination of trastuzumab, lapatinib and chemotherapy in HER2-positive metastatic breast cancer: A multi-center retrospective study
    Li, Y.
    Gong, C.
    Lu, Q.
    Zhou, Z.
    Luo, T.
    Li, W.
    Li, G.
    Ge, R.
    Wang, B.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S66 - S66
  • [26] DOES PREVIOUS NEOADJUVANT/ADJUVANT TRASTUZUMAB INFLUENCE THE DISEASE OUTCOME OF METASTATIC HER2 POSITIVE BREAST CANCER PATIENTS TREATED WITH FIRST LINE TRASTUZUMAB AND CHEMOTHERAPY
    Milosevic, Snezana
    Stanic, Nemanja
    Bozovic-Spasojevic, Ivana
    Tomasevic, Zorica
    Susnjar, Snezana
    BREAST, 2015, 24 : S41 - S42
  • [27] Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer
    Sandhya Mehta
    Jipan Xie
    Raluca Ionescu-Ittu
    Xiaoyu Nie
    Winghan J. Kwong
    Oncology and Therapy, 2023, 11 : 481 - 493
  • [28] Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+?Metastatic Breast Cancer
    Mehta, Sandhya
    Xie, Jipan
    Ionescu-Ittu, Raluca
    Nie, Xiaoyu
    Kwong, Winghan J.
    ONCOLOGY AND THERAPY, 2023, 11 (04) : 481 - 493
  • [29] Evaluating the safety of tucatinib in combination with trastuzumab and capecitabine for human epidermal growth factor 2 (HER2)-positive metastatic breast cancer in a real-world setting
    Moore, Heather
    Anders, Carey
    Sammons, Sarah L.
    Erkanli, Alaattin
    Parish, Alice
    DiCola, Christina
    CANCER RESEARCH, 2023, 83 (05)
  • [30] Real world data on Trastuzumab Deruxtecan (T-DXd) induced Interstitial Lung disease (ILD) in HER2 positive metastatic breast cancer patients at the Kent Oncology Centre
    Mohammed, S.
    Moss, C.
    Harper-Wynne, C.
    CLINICAL ONCOLOGY, 2025, 38
12345